Bristol-Myers Squibb(US:BMY) 智通财经网·2025-06-13 13:37Core Insights - Bristol-Myers Squibb (BMY.US) announced positive results from the pivotal Phase 3 trial POETYK PsA-1 (IM011-054) for deucravacitinib in treating adult patients with active psoriatic arthritis who have not previously received bDMARDs [1] - The trial met its primary endpoint, showing a significant difference in ACR20 response rates at 16 weeks between the deucravacitinib group (54.2%) and the placebo group (34.1%) [1] - The safety profile of deucravacitinib during the 16-week treatment period was consistent with previous clinical trials, including the Phase 3 POETYK PsA-2 trial and trials for moderate to severe plaque psoriasis [1] Group 1 - Deucravacitinib is a selective TYK2 inhibitor with a unique mechanism of action, targeting IL-23, IL-12, and type I interferon signaling pathways, which are critical in the pathogenesis of various immune-mediated diseases [2] - The drug achieves high selectivity by binding to the regulatory domain of TYK2, leading to allosteric inhibition of TYK2 and its downstream functions [2] - Deucravacitinib has been approved in multiple countries for the treatment of adult patients with moderate to severe plaque psoriasis [2]